Table 3. Clinical characteristics of discovery cohort.
Characteristic | Patients (N=36) |
---|---|
Sex | |
Male | 23 (63.9 %) |
Female | 13 (36.1 %) |
Median Age [y] | 59 (34-78) |
Age Category | |
< 50 y | 13 (36.1 %) |
≥ 50 y | 23 (63.9 %) |
MGMT promoter methylation status | |
Methylated | 18 (50.0 %) |
Unmethylated | 18 (50.0 %) |
Secondary Malignisation | |
Yes | 12 (33.3 %) |
No | 24 (66.7 %) |
Concomitant Temozolomide | |
Yes | 32 (88.9 %) |
No | 1 (2.8 %) |
Unknown | 3 (8.3 %) |
Median adjuvant TMZ cycles | 6 (0−20) |